Research Group Marc Pfister
Area of Research
Apply pharmacometric and systems pharmacology computer models to characterize effects of development and disease on therapeutics with the goal to individualize and optimize the use of medicines in neonates, infants and children. Investigate interplays between growth, kidney function, dialysis treatment, and pharmacotherapy. Develop AI based bedside digital health solutions such as clinical decision support tools to benefit sick children and their caregivers. Lead SwissPedPha, Swiss center for pharmacology and pharmacometrics research.
Approved Research Projects
- Pharmacology study to characterize protein binding in infants and children
- Pharmacology study to investigate pharmacokinetics and dosing of metamizole in infants
- and children
- Thy-Mod study to personalize dosing in children with hyper- or hypothyroidism
- Physical activity study to personalize insulin therapy in children with type-1 diabetes mellitus
- EPIC study to investigate copeptin and renal biomarkers in dehydrated infants and children
- KidMaCare study to investigate novel renal biomarkers in healthy infants and children and those with cancer
- ETH Basel/Zurich
- Universities of Zurich, Berne, Lausanne and Geneva
- Leadership roles in national initiatives and projects such as SwissPedNet, SwissPedDose and SwissPedPha
- University of Yale (Nephrology)
- University of Stanford (Nephrology)
- University of Florida (Pharmacometrics and Pharmacology)
- University of Constance (Mathematics)
- University of Regensburg (Neonatology)
Ongoing Research Projects
Pharmacometric and pharmacology research projects to personalize treatment/dosing in preterm- and term neonates, children with type 1 diabetes mellitus, children with hypo- or hyperthyroidism as well as children receiving renal replacement treatment.
Pharmacology research projects to investigate use of novel markers to monitor glomerular and tubular kidney function in neonates, infants and children.